Can-Fite BioPharma will present its advanced clinical-stage drug pipeline targeting cancer, liver, and inflammatory diseases at the BIO International Convention 2026. The company aims to engage potential partners for licensing and commercialization, highlighting its lead drug Namodenoson in Phase III trials for liver cancer and pancreatic cancer, and Piclidenoson in Phase III for psoriasis. Can-Fite's platform has shown safety in over 1,600 patients, and the company has secured $20 million in upfront and milestone payments from licensing deals. These efforts could expand the global reach and value of its therapies.
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
Ipsen Pharma conducted share buybacks from July 6 to July 10, 2026, purchasing a total of 28,541 shares. The average purchase price was €166.05 per share. These buybacks were made under Article 5 of the MAR regulation, indicating a structured repurch...
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
